Zimbabwe has declined a major US healthcare agreement worth 367 million US dollars (272 million pounds) over five years due to Washington's request for sensitive information.
This move came to light following a internal memorandum dated December was disclosed, indicating that Head of State Emmerson Mnangagwa felt the deal was "lopsided".
A government spokesperson later explained that the US was demanding access to health data for scientific study and profit while refused to share the benefits from future treatments.
"We will now turn to the difficult and regrettable process of scaling back our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy noted the United States had provided more than $1.9bn in health funding to Zimbabwe over the last two decades.
A medical body in Zimbabwe has appealed for further talks to find a agreement suitable to both sides so the nation's vital HIV treatment initiative can be sustained.
Broader Implications
Zimbabwe's decision comes after a comparable case in Kenya, where a high court suspended a related deal with the US after concerns were filed about the safety of citizens' health data.
Since returning to office recently, US President Donald Trump has slashed overseas assistance and shut down the key foreign aid agency.
The agency had managed aid for the US government, but Trump stated its expenditure was "wasteful" and his administration was pursuing government-to-government agreements to enhance openness and responsibility.
Based on statements, Sixteen nations in Africa have to date agreed to similar agreements, constituting more than $18.3bn in new funding.
Details of the Rejected Deal
The money for Zimbabwe would have funded "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"It is our view this cooperation might have yielded immense advantages for Zimbabwean communities, particularly the 1.2 million presently on HIV treatment through American-funded programmes," the Ambassador commented.
However, government spokesperson Nick Mangwana said the proposed deal was "unequal".
"Our nation was requested to share its biological resources and data over an extended period, with no corresponding promise of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that might be developed from that provided information," his statement read.
"In essence, our country would provide the raw materials for scientific discovery with no certainty that the end products would be accessible to our people should a new pandemic emerge."
National Interest and International Frameworks
He also said that the American exit from the global health body and its push of bilateral health agreements were undermining structures already established through the global health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework designed to manage potential global health emergencies.
"This framework is intended to guarantee that when a nation provides its data, the resulting advantages – including vaccines and treatments – are shared equitably, not monopolised exclusively by those with the funds to develop them."
These objections over the US deal "must not be interpreted as anti-American sentiment," he added.
"We are open to continued discussions with our US partners on how future collaboration could be arranged in a way that honours the sovereignty and dignity of each country."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the official position, but suggested that talks must proceed since much of the nation's HIV programmes were funded by international support.
"In cases where specific concerns arise, including those involving information security or implementation frameworks, these can often be resolved via technical clarification and mutually agreed protections," the group commented.
The situation highlights the ongoing debate between accepting crucial international aid and protecting a country's data in an increasingly data-driven world.